Investors remain optimistic about Shanghai Haohai Biological Technology's future, judging by its high P/E ratio. Strong growth predictions continue to bolster shareholder support but alterations to these conditions may impact the sustained backing.

Analysts are increasingly positive about Shanghai Haohai Biological Technology's performance, despite growth prospects slower than the industry average. They believe the company's intrinsic value is on an upswing.

Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...